Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A 2-Part Study to Assess the Safety and Tolerability, pk, Effects on Histology and Some Clinical Parameters of Givinostat in Ambulant Children With DMD

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Italfarmaco Identifier:
First received: December 20, 2012
Last updated: March 1, 2017
Last verified: March 2017
This is a 2-part, phase 2 study to assess the effects of Givinostat on muscle histologic parameters and on clinical parameters in ambulant children with DMD. The safety, tolerability, and pharmacokinetics of Givinostat will also be assessed. All children treated in part 2 continue in the extension phase, for a maximum of an additional 12 months.

Condition Intervention Phase
Duchenne Muscular Dystrophy (DMD)
Drug: Givinostat
Phase 1
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Two-Part Study to Assess the Safety and Tolerability, Pharmacokinetics, and Effects on Histology and Different Clinical Parameters of Givinostat in Ambulant Children With Duchenne Muscular Dystrophy

Resource links provided by NLM:

Further study details as provided by Italfarmaco:

Primary Outcome Measures:
  • Change in the value of MFA% comparing the histology biopsies before and after 12 months of treatment with Givinostat. [ Time Frame: baseline and 12 months ]

Secondary Outcome Measures:
  • Change in additional histological endpoints (i.e., cross-sectional area, inflammation, necrosis, fibrosis, and muscle regeneration) after 12 months of treatment with Givinostat at the selected daily dose [ Time Frame: baseline and 12 months ]
  • Change in muscular function after 12 months of treatment with Givinostat at the selected daily dose based on the 6MWT, NSAA and PUL [ Time Frame: baseline and 12 months ]
  • Type, incidence, and severity of treatment-emergent AEs and SAEs correlated with dose [ Time Frame: baseline and 12 months ]

Other Outcome Measures:
  • Individual Givinostat concentrations tabulated by dose cohort along with descriptive statistics for Part 1 and tabulated along with descriptive statistic for Part 2. [ Time Frame: baseline and 12 months ]
  • Change in muscle, fat and fibrosis content after treatment with Givinostat as measured by MRI [ Time Frame: baseline and 12 months ]

Enrollment: 20
Study Start Date: May 2013
Estimated Study Completion Date: August 2017
Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Givinostat
Givinostat will be administered as 2 oral doses daily while the child is in fed state.
Drug: Givinostat

Detailed Description:

Approximately 20 children will be enrolled in the study as follows: the first 4 children will be treated at a low dose level of Givinostat.

If none of the stopping criteria described in the study protocol are met after 2 weeks of treatment at the low dose, the review team will determine the escalated dose level (i.e., intermediate dose level) to be used for the treatment of an additional 8 children who will be treated at the intermediate dose. The 4 children previously treated at the low dose level will also be switched to the intermediate dose level.

If none of the stopping criteria are met after 2 weeks of treatment at the intermediate dose, the review team will determine the subsequent escalated dose level to be used for the treatment of an additional 8 children who will be treated at the high dose. All children treated at the intermediate dose level will be switched to the high dose level.

Once all 20 children enrolled during the Part 1 of the study have been treated for at least 2 weeks, the review team will determine the recommended dose (RD) to be used in Part 2 based on the safety and tolerability profile observed and on the pharmacokinetic (PK) analyses. All the children enrolled will switch to the RD level, which will be administered for the subsequent 12 months of the study (Part 2).

The additional children (if any) will be enrolled during Part 2 of the study and will receive the RD of Givinostat for 12 months.

The total duration of the study is 15 months and an additional 12 months for the extension phase.


Ages Eligible for Study:   7 Years to 11 Years   (Child)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male children aged 7 to <11 years with an immunohistochemical and molecular diagnosis of DMD.
  2. A parent/guardian and child can comply with all study evaluations/procedures and return for all study activities.
  3. Able to complete the 2 screening 6MWTs with a minimal distance of at least 250 m each. In addition, the results of these tests must be within ±30 m of each other.
  4. On a stable dose of systemic corticosteroids for at least 6 months.
  5. At least 6 months worth of data on the 6MWT (this will be the "historical" 6MWT). From the moment of the historical 6MWT assessment(s), the child must not have received any compound that could potentially affect the 6MWT, with the exception of the stable steroid treatment.
  6. Parent/guardian has signed the informed consent form and child has assented to be in the study (if applicable).

Exclusion Criteria:

  1. Initiation of systemic corticosteroid therapy within 6 months prior to the start of study drug or change in systemic corticosteroid therapy (e.g., initiation, change in type of drug, dose modification not related to body weight change, schedule modification, interruption, discontinuation, or re initiation) within 6 months prior to the start of study drug.
  2. Use of any pharmacologic treatment, other than corticosteroids, that might have an effect on muscle strength since the time of the historical 6MWT and in any case within 3 months prior to the start of study treatment (e.g., growth hormone). Vitamin D, calcium, and integrators will be allowed.
  3. Surgery that might have an effect on muscle strength or function within 3 months before study entry or planned surgery at any time during the study.
  4. Exposure to another investigational drug since the time of the historical 6MWT and in any case within 3 months prior to the start of study treatment.
  5. History of participation in gene therapy, cell-based therapy or oligonucleotide therapy.
  6. Presence of other clinically significant disease that in the opinion of the investigator places the child in unacceptable risk for an adverse outcome or that could affect study results.
  7. Symptomatic cardiomyopathy or heart failure. If child has a left ventricular ejection fraction <45% at screening, the investigator should discuss inclusion of child in the study with the medical monitor.
  8. Inadequate hematological function
  9. Absolute neutrophil count: <1.5 x 109/L
  10. Platelets: <100 x 109/L
  11. Current or history of liver disease or impairment, including but not limited to an elevated total bilirubin.
  12. Inadequate renal function, as defined by serum creatinine >2 x the upper limit of normal.
  13. Positive test for hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus at screening
  14. A baseline QTc >450 msec, (as the mean of 3 consecutive readings 5 minutes apart) or history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia, family history of long QT syndrome).
  15. Psychiatric illness/social situations rendering the potential child unable to understand and comply with the study protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01761292

Azienda Ospedaliera Universitaria Policlinico G. Martino
Messina, Italy, 98125
IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano
Milano, Italy, 20122
Policlinico Agostino Gemelli
Roma, Italy, 00168
Ospedale Pediatrico Bambino Gesù
Rome, Italy, 00165
Sponsors and Collaborators
  More Information

Responsible Party: Italfarmaco Identifier: NCT01761292     History of Changes
Other Study ID Numbers: DSC/11/2357/43
2012-002566-12 ( EudraCT Number )
Study First Received: December 20, 2012
Last Updated: March 1, 2017

Additional relevant MeSH terms:
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked processed this record on May 22, 2017